Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 8/20 | 0.51 |
| ▸ | LIPG | Q9Y5X9 | 8/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 8/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.40 |
| ▸ | SNCA | P37840 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13857889 | 0.86 | LPL (0.54) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL4380517 | 0.83 | LPL (0.54) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL17423585 | 0.83 | LPL (0.50) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL13863262 | 0.82 | LPL (0.53) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL25981268 | 0.81 | LPL (0.48) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL368960 | 0.81 | LPL (0.71) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL14972496 | 0.80 | LPL (0.45) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL14746587 | 0.78 | LPL (0.44) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL4378064 | 0.77 | LPL (0.53) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL13860126 | 0.77 | LPL (0.56) | LPLLIPGCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249192-A1 | NOVEL HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. | 2010-09-30 | — | — | US | disclosed |
| EP-2231649-A1 | NOVEL HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | Merck Frosst Canada Ltd. (CA) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009073973-A1 | NOVEL HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249192-A1 | NOVEL HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | SCD, SCD5, SREBF1 | LPL 242/4885LIPG 119/4885CA1 4857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.